CIK 0000949858 · Non-accelerated filer<br>Smaller reporting company
ACHIEVE LIFE SCIENCES, INC.
Sign in to watch- Ticker
- ACHV
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 954343413
- Phone
- 425-686-1500
- Business address
- 22722 29TH DR. SE, SUITE 100, SEATTLE, WA, 98021
- Former names
- ONCOGENEX PHARMACEUTICALS, INC., SONUS PHARMACEUTICALS INC
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Option exercise Director acquired 2,500 shares (option exercise)
- 4 Option exercise Director acquired 2,500 shares (option exercise)
- 4 Option exercise Director acquired 2,500 shares (option exercise)
- 4 Option exercise Director acquired 5,000 shares (option exercise)
- 4 Option exercise Director acquired 2,500 shares (option exercise)
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- DEFC14A Other DEFC14A
- CORRESP Other Correspondence Between Filers and SEC Staff
- PRER14A Other PRER14A
- UPLOAD Other SEC-generated Letter
- PREC14A Other PREC14A
- PRE 14A Proxy Proxy Statement (Preliminary)
- 4 Open-market sale EVP, CMO sold 3,254 shares at $0.83 ($2,701)
- 4 Open-market sale CFO sold 834 shares at $0.83 ($692)
- 4 Open-market sale President and CEO sold 12,033 shares at $0.83 ($9,987)
- 10-K Report Annual Report
Page 33 of 68 · 1,358 filings